TOI — Oncology Institute Share Price
0.000.00%
Last trade - 00:00- $39.01m
- $61.56m
- $324.24m
- 27
- 73
- 18
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.79 | ||
| Price to Tang. Book | 1.94 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.1 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -39.13% | ||
| Return on Equity | -85.39% | ||
| Operating Margin | -18.13% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 155.41 | 187.51 | 203 | 252.48 | 324.24 | 414.66 | 482.8 | 23.43% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at 83 clinic locations across 15 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion and dispensary, radiation, programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. It also provides management services to 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- November 1st, 2019
- Public Since
- March 13th, 2020
- No. of Shareholders
- 72
- No. of Employees
- 800
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 74,437,924
- Address
- 18000 Studebaker Rd, Suite 800, CERRITOS, 90703
- Web
- https://theoncologyinstitute.com/
- Phone
- +1 5627353226
- Auditors
- BDO USA, LLP
Upcoming Events for TOI
Q2 2024 Oncology Institute Inc Earnings Release
Q3 2024 Oncology Institute Inc Earnings Release
Similar to TOI
23andMe Holding Co.
NASDAQ Capital Market
ADVANCED BIOMED
NASDAQ Capital Market
Akanda
NASDAQ Capital Market
Assure Holdings
NASDAQ Capital Market
Astrana Health
NASDAQ Capital Market
FAQ
What is the Oncology Institute share price?
As of Today at 16:29 UTC, shares in Oncology Institute are trading at $0.44. This share price information is delayed by 15 minutes.
How has the Oncology Institute share price performed this year?
Shares in Oncology Institute last closed at $0.44 and the price had moved by -18.27% over the past 365 days. In terms of relative price strength the Oncology Institute share price has underperformed the S&P500 Index by -34.97% over the past year.
What are the analyst and broker recommendations for Oncology Institute?
The overall consensus recommendation for Oncology Institute is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Oncology Institute dividend yield?
Oncology Institute does not currently pay a dividend.
Does Oncology Institute pay a dividend?
Oncology Institute does not currently pay a dividend.
When does Oncology Institute next pay dividends?
Oncology Institute does not currently pay a dividend.
How do I buy Oncology Institute shares?
To buy shares in Oncology Institute you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Oncology Institute?
As of the previous close price of $0.44, shares in Oncology Institute had a market capitalisation of $32.83m.
Where are Oncology Institute shares listed?
Here are the trading details for Oncology Institute:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TOI
What kind of share is Oncology Institute?
Based on an overall assessment of its quality, value and momentum Oncology Institute is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Oncology Institute share price forecast for 2024?
The analyst consensus target price for shares in Oncology Institute is $2.00. That is 353.51% above the last closing price of $0.44.
Analysts covering Oncology Institute currently have a consensus Earnings Per Share (EPS) forecast of -$0.42 for the next financial year.
What is the trend in the Oncology Institute share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncology Institute. Over the past six months, its share price has underperformed the S&P500 Index by -78.11%.
As of the last closing price of $0.44, shares in Oncology Institute were trading -70.93% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Oncology Institute PE Ratio?
The Oncology Institute PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.44.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Oncology Institute?
We do not have data on Oncology Institute's directors